Antibody response after application of a new live attenuated mumps vaccine (Pariorix) measured by enzyme-linked immunosorbent assay (ELISA).
Mumps virus specific antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), hemolysis-in-gel (HIG) test, and hemagglutination-inhibition (HI) test in 17 adult volunteers before and after vaccination with a new live mumps vaccine, Pariorix. The results of the present study indicate that the strain Urabe-Am 9 of the mumps virus (Pariorix) induces antibodies in 100% of seronegative adults when measured by ELISA and in 70.6% and 64.7% in HIG and HI, respectively. ELISA is therefore a very sensitive and reliable method for the demonstration of sero-conversion after vaccination. The vaccine was well tolerated and clinically acceptable in the group of adult volunteers.
D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis*; D000917:Antibody Formation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006462:Hemolytic Plaque Technique; D006801:Humans; D008297:Male; D009108:Mumps Vaccine / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000276:immunology
D000914:Antibodies, Viral; D009108:Mumps Vaccine; D014613:Vaccines, Attenuated